blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3590516

EP3590516 - ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  08.12.2023
Database last updated on 28.05.2024
FormerRequest for examination was made
Status updated on  06.12.2019
FormerThe international publication has been made
Status updated on  11.09.2018
Most recent event   Tooltip28.02.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Taiho Pharmaceutical Co., Ltd.
1-27 Kandanishiki-cho Chiyoda-ku
Tokyo 101-8444 / JP
[2020/02]
Inventor(s)01 / IRIE, Hiroki
c/o Taiho Pharmaceutical Co., Ltd.
3 Okubo
Tsukuba-shi Ibaraki 300-2611 / JP
02 / OGUCHI, Kei
c/o Taiho Pharmaceutical Co., Ltd.
3 Okubo
Tsukuba-shi Ibaraki 300-2611 / JP
03 / FUJIOKA, Yayoi
c/o Taiho Pharmaceutical Co., Ltd.
3 Okubo
Tsukuba-shi Ibaraki 300-2611 / JP
 [2020/02]
Representative(s)Blodig, Wolfgang
Wächtershäuser & Hartz
Patentanwaltspartnerschaft mbB
Weinstrasse 8
80333 München / DE
[2020/02]
Application number, filing date18761224.727.02.2018
[2020/02]
WO2018JP07277
Priority number, dateJP2017003701928.02.2017         Original published format: JP 2017037019
[2020/02]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018159613
Date:07.09.2018
Language:JA
[2018/36]
Type: A1 Application with search report 
No.:EP3590516
Date:08.01.2020
Language:EN
[2020/02]
Search report(s)International search report - published on:JP07.09.2018
(Supplementary) European search report - dispatched on:EP10.11.2020
ClassificationIPC:A61K31/519, A61P35/00, A61P43/00, C07D487/04, A61K31/513, A61K31/337, A61K31/436, A61K31/4745, A61K31/5377, A61K31/553, A61K31/7068, A61K31/7072, A61K33/243, A61K39/395, A61K45/06, C07K16/32
[2020/50]
CPC:
C07K16/32 (EP); C07D487/04 (EP,KR); A61K31/519 (EP,KR,US);
A61K31/337 (EP,US); A61K31/436 (EP); A61K31/437 (US);
A61K31/439 (US); A61K31/4745 (EP); A61K31/513 (EP,US);
A61K31/5377 (EP,US); A61K31/553 (EP,US); A61K31/7068 (EP,US);
A61K31/7072 (EP); A61K33/24 (KR); A61K33/243 (EP,US);
A61K39/39558 (EP); A61K45/00 (KR); A61K45/06 (EP,US);
A61P35/00 (EP,KR,US); A61P43/00 (KR) (-)
C-Set:
A61K31/337, A61K2300/00 (EP);
A61K31/436, A61K2300/00 (EP);
A61K31/4745, A61K2300/00 (EP);
A61K31/513, A61K2300/00 (EP);
A61K31/519, A61K2300/00 (EP);
A61K31/5377, A61K2300/00 (EP);
A61K31/553, A61K2300/00 (EP);
A61K31/7068, A61K2300/00 (EP);
A61K31/7072, A61K2300/00 (EP);
A61K33/243, A61K2300/00 (EP);
A61K39/39558, A61K2300/00 (EP);
A61K45/06, A61K2300/00 (EP)
(-)
Former IPC [2020/02]A61K31/519, A61K33/24, A61K45/00, A61P35/00, A61P43/00, C07D487/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/02]
Extension statesBA10.09.2019
ME10.09.2019
Validation statesMA10.09.2019
MD10.09.2019
TN10.09.2019
TitleGerman:ANTITUMORWIRKUNGSVERSTÄRKER MIT PYRAZOLO[3,4-D]PYRIMIDIN-VERBINDUNG[2020/02]
English:ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND[2020/02]
French:ACTIVATEUR D'EFFET ANTITUMORAL UTILISANT UN COMPOSÉ PYRAZOLO[3,4-D]PYRIMIDINE[2020/02]
Entry into regional phase10.09.2019Translation filed 
10.09.2019National basic fee paid 
10.09.2019Search fee paid 
10.09.2019Designation fee(s) paid 
10.09.2019Examination fee paid 
Examination procedure10.09.2019Examination requested  [2020/02]
07.06.2021Amendment by applicant (claims and/or description)
07.12.2023Despatch of a communication from the examining division (Time limit: M02)
06.02.2024Reply to a communication from the examining division
Fees paidRenewal fee
29.02.2020Renewal fee patent year 03
28.02.2021Renewal fee patent year 04
28.02.2022Renewal fee patent year 05
28.02.2023Renewal fee patent year 06
28.02.2024Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2007067781  (ABBOTT LAB [US], et al) [A] 1-9 * claims 1, 6-9 *;
 [A]WO2012006552  (EXELIXIS INC [US], et al) [A] 1-9 * paragraph [0174] * * paragraph [0186] - paragraph [0189] * * paragraph [0228] - paragraph [0229] * * example 10 *;
 [E]EP3345907  (TAIHO PHARMACEUTICAL CO LTD [JP]) [E] 2-6 * paragraph [0242] - paragraph [0245] * * paragraph [0502] - paragraph [0511] * * claims 1-18 *;
 [A]  - JOOST C. M. UITDEHAAG ET AL, "Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs", PLOS ONE, (20150527), vol. 10, no. 5, doi:10.1371/journal.pone.0125021, page e0125021, XP055485736 [A] 1-9 * abstract * * page 17 *

DOI:   http://dx.doi.org/10.1371/journal.pone.0125021
International search[A]JP2009518434  (ABBOTT LABORATORIES) [A] 1-36 * , entire text & US 2007/0135387 A1 & WO 2007/067781 A2 & EP 1968979 A2 *;
 [A]WO2013108809  (TAIHO PHARMACEUTICAL CO LTD [JP]) [A] 1-36 * , entire text & US 2014/0343035 A1 & EP 2657233 A1 *;
 [A]WO2015022926  (TAIHO PHARMACEUTICAL CO LTD [JP]) [A] 1-36 * , entire text & US 2016/0115168 A1 & EP 2947086 A1 *;
 [PXA]WO2017038838  (TAIHO PHARMACEUTICAL CO LTD [JP]) [PX] 10-17 * , claims 1-18 & US 2017/0217970 A1, claims 1-9 * [PA] 1-9, 18-36;
 [A]  - ZHANG, C. et al., "Disign,Synthesis, and Structure- Activity Relationship Studies of 3- (Phenylethynyl)-lH-pyrazolo[3, 4-d]pyrimidin-4- amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer", Journal of Medicinal Chemistry, vol. 58, no. 9, (20150416), pages 3957 - 3974, URL: doi:10.1021/acs.jmedchem.5b00270, XP055365177 [A] 1-36 * , in particular, compound 1r in table 2 *

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.5b00270
by applicantWO2007126841
 WO2012058134
    - Oncogene, (20070000), vol. 26, pages 6469 - 6487
    - Cancer Treat. Rev., (20140000), vol. 40, pages 770 - 780
    - Genes Cancer, (20130000), vol. 4, pages 187 - 195
    - Oncogene, (20000000), vol. 19, pages 1647 - 1656
    - N. Engl. J. Med., (20010000), vol. 344, pages 783 - 792
    - J. Natl. Cancer Inst., (20040000), vol. 96, pages 759 - 769
    - Breast Cancer, (20140000), vol. 21, pages 677 - 683
    - Oncol. Rep., (20120000), vol. 27, pages 1639 - 1645
    - Mol. Cancer Ther., (20100000), vol. 9, pages 1198 - 1207
    - "Iyakuhin no Kaihatsu (Development of drugs in English", Molecular Design, Hirokawa-Shoten Ltd., (19900000), vol. 7, pages 163 - 198
    - European Journal of Medicinal Chemistry, (20100000), vol. 46, no. 1, pages 285 - 296
    - PLoS One, (20110000), vol. 6, no. 7, page e21487
    - Trends Pharmacol. Sci., (19830000), vol. 4, pages 450 - 454
    - Pharmacol Rev., (20060000), vol. 58, no. 3, pages 621 - 81
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.